Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel versus mitoxantrone as second-line rescue chemotherapy for metastatic castration-resistant prostate cancer
ChiCTR1900021648Phase 2Not yet recruiting
- Sponsor
- Yancheng First People's Hospital
- Start
- May 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and mitoxantrone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Yancheng First People's Hospital. Primary endpoint: Progression-free survival. Planned start May 2019; status: not yet recruiting.
02
Drugs
paclitaxelmitoxantrone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR1900021648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021648.